Advances in the use of cell penetrating peptides for respiratory drug delivery
Introduction: Respiratory diseases are leading causes of death in the world, still inhalation therapies are the largest fail in drug development. There is an evident need to develop new therapies. Biomolecules represent apotential therapeutic agent in this regard, however their translation to the clinic is hindered by the lack of tools to efficiently deliver molecules. Cell penetrating peptides (CPPs) have arisen as apotential strategy for intracellular delivery that could theoretically enable the translation of new therapies.Areas covered: In this review, the use of CPPs as astrategy to deliver different molecules (cargoes) to treat lung-relateddiseases will be the focus. Abrief description of these molecules and the innovative methods in designing new CPPs is presented. The delivery of different cargoes (proteins, peptides, poorly soluble drugs and nucleic acids) using CPPs is discussed, focusing on benefits to treat different respiratory diseases like inflammatory disorders, cystic fibrosis and lung cancer.Expert opinion: The advantages of using CPPs to deliver biomolecules and poorly soluble drugs to the lungs is evident. This field has advanced in the past few years toward targeted intracellular delivery, although further studies are needed to fully understand its potential and limitations in vitro and in vivo.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Expert opinion on drug delivery - 17(2020), 5 vom: 02. Mai, Seite 647-664 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gomes Dos Reis, Larissa [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.12.2020 Date Revised 29.12.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/17425247.2020.1739646 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM307270564 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM307270564 | ||
| 003 | DE-627 | ||
| 005 | 20231225125210.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/17425247.2020.1739646 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1024.xml |
| 035 | |a (DE-627)NLM307270564 | ||
| 035 | |a (NLM)32138567 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gomes Dos Reis, Larissa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Advances in the use of cell penetrating peptides for respiratory drug delivery |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.12.2020 | ||
| 500 | |a Date Revised 29.12.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Introduction: Respiratory diseases are leading causes of death in the world, still inhalation therapies are the largest fail in drug development. There is an evident need to develop new therapies. Biomolecules represent apotential therapeutic agent in this regard, however their translation to the clinic is hindered by the lack of tools to efficiently deliver molecules. Cell penetrating peptides (CPPs) have arisen as apotential strategy for intracellular delivery that could theoretically enable the translation of new therapies.Areas covered: In this review, the use of CPPs as astrategy to deliver different molecules (cargoes) to treat lung-relateddiseases will be the focus. Abrief description of these molecules and the innovative methods in designing new CPPs is presented. The delivery of different cargoes (proteins, peptides, poorly soluble drugs and nucleic acids) using CPPs is discussed, focusing on benefits to treat different respiratory diseases like inflammatory disorders, cystic fibrosis and lung cancer.Expert opinion: The advantages of using CPPs to deliver biomolecules and poorly soluble drugs to the lungs is evident. This field has advanced in the past few years toward targeted intracellular delivery, although further studies are needed to fully understand its potential and limitations in vitro and in vivo | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COPD | |
| 650 | 4 | |a Lung | |
| 650 | 4 | |a aerosol drug delivery | |
| 650 | 4 | |a asthma | |
| 650 | 4 | |a cancer | |
| 650 | 4 | |a cystic fibrosis | |
| 650 | 4 | |a designing tools | |
| 650 | 4 | |a inflammatory diseases | |
| 650 | 4 | |a machine-learning | |
| 650 | 4 | |a poorly soluble drugs | |
| 650 | 7 | |a Cell-Penetrating Peptides |2 NLM | |
| 650 | 7 | |a Nucleic Acids |2 NLM | |
| 650 | 7 | |a Pharmaceutical Preparations |2 NLM | |
| 650 | 7 | |a Proteins |2 NLM | |
| 700 | 1 | |a Traini, Daniela |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on drug delivery |d 2004 |g 17(2020), 5 vom: 02. Mai, Seite 647-664 |w (DE-627)NLM159019028 |x 1744-7593 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2020 |g number:5 |g day:02 |g month:05 |g pages:647-664 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/17425247.2020.1739646 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2020 |e 5 |b 02 |c 05 |h 647-664 | ||